Similarly, our group observed that employing recombinant thioredoxin (rTRx), another critical antioxidant molecule, programmed antitumor CD8+ T cells with high spare respiratory capacity and increased the persistence of T cells in vivo and led to enhanced tumor control upon ACT [41]. This evidence concerns the gene CD8A and neoplasm.